Qutoutiao Inc (NASDAQ: QTT)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | -31.11 |
---|---|
% Price Change (last 13 weeks): | -17.88 |
% Price Change (last 26 weeks): | 66.22 |
% Price Change (last 52 weeks): | 18.66 |
% Price Change (year to date): | 64.93 |
Return on Equity (%): | -90.02 |
---|---|
Return on Assets (%): | -42.26 |
Return on Invested Capital (%): | -46.41 |
Gross Profit Margin (%): | 50.00 |
---|---|
Net Profit Margin (%): | -9771.71 |
Operating Profit Margin (%): | -7967.30 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
|
Qutoutiao Inc
830 Winter Street 2nd floor Waltham MA 02451 Phone: n/a Fax: n/a http://www.q32bio.com |
Earnings (1year) ($): | -35.16 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 22.65 |
Cash Flow ($): | -34.87 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 30.42 |
Price/Book (x): | 0.48 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 7.25 |
---|---|
Current Ratio (x): | 7.25 |
LT Debt/Equity (x): | 0.00 |
Total Debt/Equity (x): | 1.81 |